|
| 35939786 | Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling. | Blood Adv | 2023 |
| 37685882 | Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge. | Int J Mol Sci | 2023 |
| 37088803 | NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. | Blood Cancer J | 2023 |
| 36441905 | Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. | Blood Adv | 2023 |
| 34482403 | Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. | Blood | 2022 |
| 36307214 | Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia. | Cold Spring Harb Mol Case Stud | 2022 |
| 35258401 | Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome. | Leuk Lymphoma | 2022 |
| 33961341 | Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. | Am J Transplant | 2021 |
| 33901720 | Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. | Transplant Cell Ther | 2021 |
| 34559205 | In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. | Blood Adv | 2021 |
| 34496019 | A novel activating JAK1 mutation in chronic eosinophilic leukemia. | Blood Adv | 2021 |
| 34250402 | BCR-ABL+ Chronic Myeloid Leukemia Arising in a Family With Inherited ANKRD26-Related Thrombocytopenia. | JCO Precis Oncol | 2021 |
| 31848884 | Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. | Mol Diagn Ther | 2020 |
| 31844143 | Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. | Leukemia | 2020 |
| 31866570 | Molecular Discordance between Myeloid Sarcomas and Concurrent Bone Marrows Occurs in Actionable Genes and Is Associated with Worse Overall Survival. | J Mol Diagn | 2020 |
| 31880950 | Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | J Clin Oncol | 2020 |
| 31026597 | Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA. | J Mol Diagn | 2019 |
| 30810217 | Phenotype switch in acute lymphoblastic leukaemia associated with 3Â years of persistent CAR T cell directed-CD19 selective pressure. | Br J Haematol | 2019 |
| 31124175 | Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. | Am J Hematol | 2019 |
| 31145495 | The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. | Am J Hematol | 2019 |
| 29165010 | DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. | Leuk Lymphoma | 2018 |
| 29959414 | Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. | Leukemia | 2018 |
| 30348809 | A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. | Cancer Res | 2018 |
| 27412040 | Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. | Leuk Lymphoma | 2017 |
| 29078326 | CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. | Proc Natl Acad Sci U S A | 2017 |
| 28815200 | The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. | Acad Pathol | 2017 |
| 27761930 | Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. | Am J Hematol | 2017 |
| 27109508 | Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. | Leukemia | 2016 |
| 26573090 | Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. | Am J Hematol | 2016 |
| 27124934 | Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. | Am J Clin Pathol | 2016 |
| 27124787 | Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists. | Genet Med | 2016 |
| 27235757 | Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. | Exp Hematol | 2016 |
| 25421800 | Next generation sequencing in clinical diagnostics: experiences of early adopters. | Clin Chem | 2015 |
| 26231802 | MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. | Ann Hematol | 2015 |
| 26071326 | The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. | J Clin Virol | 2015 |
| 25132497 | BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. | Cancer Cell | 2014 |
| 25003357 | Clinical implementation of next-generation sequencing. | Clin Adv Hematol Oncol | 2014 |
| 25180155 | Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. | Leuk Res Rep | 2014 |
| 23810242 | BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. | J Mol Diagn | 2013 |
| 24063401 | BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring. | Expert Rev Mol Diagn | 2013 |
| 23666688 | Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. | Methods Mol Biol | 2013 |
| 23666687 | Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia. | Methods Mol Biol | 2013 |
| 22658276 | Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. | Hum Pathol | 2012 |
| 21502425 | Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. | Am J Clin Pathol | 2011 |
| 21860020 | TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. | Blood | 2011 |
| 21908430 | The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Blood | 2011 |
| 20566700 | Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy. | Oncologist | 2010 |
| 20720184 | Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. | Blood | 2010 |
| 20519627 | BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. | Blood | 2010 |
| 19225134 | Multi-Site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: a report of the association for molecular pathology. | J Mol Diagn | 2009 |